2018
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma
Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian carcinomaSerous ovarian carcinomaIL-6Ovarian cancerOvarian carcinomaE-cadHigh-grade serous ovarian adenocarcinomaEarly-stage ovarian cancerROC analysisEarly detectionMajority of patientsLethal gynecologic malignancyStage ovarian cancerOvarian cancer patientsBenign gynecologic pathologyNon-cancer controlsSerous ovarian adenocarcinomaEffective cancer screeningSerous ovarian cancerMultiple biomarker panelsFour-marker panelHigh differential gene expressionGynecologic malignanciesCA 125IL-1ra
2005
Consolidation therapy for ovarian cancer
Huang G, Goldberg G, Fields A. Consolidation therapy for ovarian cancer. The Women's Oncology Review 2005, 5: 3-8. DOI: 10.3109/14733400500070708.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsWhole abdominal radiotherapyConsolidation therapyOvarian cancerCatheter-related complicationsRecurrence-free intervalLate radiation toxicityConsolidation regimensPaclitaxel therapyOverall survivalSurvival benefitBiologic agentsRandomized studyCA 125Randomized trialsRadiation toxicityMEDLINE searchTherapyCancerToxic agentsClinical acceptanceRadiotherapyInternational meetingsRegimensChemotherapyComplications